df176ce612
Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
3.2 KiB
3.2 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Requires health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes | Requires health insurance policies and medicaid to cover biomarker precision medical testing for diagnosis, treatment, or appropriate management of, or ongoing monitoring to guide treatment decisions for, a covered person's disease or condition when the test has recognized efficacy and appropriateness for such purposes. | us/states/ny | New York Legislature | 2023-2024 | A 8502 | New York A 8502 (2023-2024) |
|
enacted |
|
1 | 15 | 2 | 2024-01-04 | 2024-02-07 | openstates | ocd-bill/a0dfeabf-5e0c-4c70-81f5-21896bd0e9ea | http://www.nysenate.gov/legislation/bills/2023/A8502 | bdfd5d26b11cdb0881299f71dc91393f4d5308f4681313426231f84e8b7dea71 | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
New York A 8502 (2023-2024) — Requires health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes
Requires health insurance policies and medicaid to cover biomarker precision medical testing for diagnosis, treatment, or appropriate management of, or ongoing monitoring to guide treatment decisions for, a covered person's disease or condition when the test has recognized efficacy and appropriateness for such purposes.
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
- A8502 (committee substitute) — source
Votes
- Assembly Vote — 146–2 (pass) · lower
- Floor Vote — 59–0 (pass) · upper
Sponsors
- Pamela J. Hunter — primary (person)
- Aileen Gunther — cosponsor (person)
- Angelo Santabarbara — cosponsor (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2024-01-04 REFERRED TO INSURANCE
referral-committee - 2024-01-08 REPORTED REFERRED TO WAYS AND MEANS
referral-committee - 2024-01-22 REPORTED REFERRED TO RULES
referral-committee - 2024-01-22 REPORTED
- 2024-01-22 RULES REPORT CAL.4
- 2024-01-22 ORDERED TO THIRD READING RULES CAL.4
- 2024-01-23 PASSED ASSEMBLY
passage - 2024-01-23 DELIVERED TO SENATE
- 2024-01-23 REFERRED TO RULES
referral-committee - 2024-01-29 SUBSTITUTED FOR S8040
- 2024-01-29 3RD READING CAL.40
- 2024-01-29 PASSED SENATE
passage - 2024-01-29 RETURNED TO ASSEMBLY
- 2024-02-07 DELIVERED TO GOVERNOR
executive-receipt - 2024-02-07 SIGNED CHAP.29
executive-signature
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/a0dfeabf-5e0c-4c70-81f5-21896bd0e9ea. Confidence: reported (aggregated from official New York legislature records).